Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Operating Margin (2018 - 2025)

Historic Operating Margin for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to 1558.58%.

  • X4 Pharmaceuticals' Operating Margin rose 46021300.0% to 1558.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 290.69%, marking a year-over-year increase of 20143000.0%. This contributed to the annual value of 1400.04% for FY2024, which is N/A changed from last year.
  • Per X4 Pharmaceuticals' latest filing, its Operating Margin stood at 1558.58% for Q3 2025, which was up 46021300.0% from 1329.55% recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Operating Margin high stood at 12629.31% for Q2 2024, and its period low was 6160.71% during Q3 2024.
  • Its 4-year average for Operating Margin is 1141.61%, with a median of 1979.76% in 2022.
  • Over the last 5 years, X4 Pharmaceuticals' Operating Margin had its largest YoY gain of 46021300bps in 2025, and its largest YoY loss of -139588600bps in 2025.
  • Quarter analysis of 4 years shows X4 Pharmaceuticals' Operating Margin stood at 2235.75% in 2022, then increased by 18bps to 2642.38% in 2023, then tumbled by -192bps to 2418.08% in 2024, then surged by 36bps to 1558.58% in 2025.
  • Its Operating Margin stands at 1558.58% for Q3 2025, versus 1329.55% for Q2 2025 and 32.78% for Q1 2025.